Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Noble Corporation plc (NE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Noble Corporation plc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $286.01 (market cap $39.89B), while Noble Corporation plc trades at $41.39 (market cap $6.38B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 6.3× Noble Corporation plc's market cap, and Noble Corporation plc pays a 5% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | NE | |
|---|---|---|
Market Cap | $39.89B | $6.38B |
Sector | Health | Technology |
52-Week High | $491.22 | $54.37 |
52-Week Low | $278.09 | $25.70 |
Enterprise Value | $38.15B | $7.63B |
Dividend Yield | — | 5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Noble Corporation (NE) trades at $39.97, up 2.75% today, with a bearish technical signal and mixed quarterly earnings. The company maintains solid cash flow, with $228M net cash flow in 2025, and recently secured a three-well UKCS contract from BP. Valuation metrics show a P/E of 27.95 and EV/EBITDA of 7.2, while analyst consensus is divided with a $50 price target.
Outlook is cautious due to recent earnings misses and bearish technicals, but strong operational cash flow and new contracts offer stability. Risks include execution challenges and oil market volatility, while the dividend and low leverage provide shareholder support. Investors should weigh fundamental strength against near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →
